Competition & Peer Data API & CSV Delivery

Alterola Biotech Inc's Competitiveness

Name: Alterola Biotech Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Alterola Biotech Inc (ALTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2024

Competitors Tracked

Publicly traded peers

Peer Group Market Share

Share of combined sales, Q2 2024

Revenue Growth Y/Y

Peers: 0.20 %

Net Margin

Peers: 11.44 %

Key Findings: Alterola Biotech Inc vs Its Competitors

TTM: Trailing 12-month revenue of 252M vs 138,958M combined for tracked competitors (0.2% combined share).

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ALTA/competitors                    

                        https://api.csimarket.com/api/v1/companies/ALTA/relationships                    

                        https://api.csimarket.com/api/v1/companies/ALTA/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Alterola Biotech Inc vs. its Competitors, Q2 2024

TTM net margin

Alterola Biotech Inc -1.1 %

Competitors combined +9.1 %

TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.

Competitor Financial Benchmarking - TTM Commercial

TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Alterola Biotech Inc and its 4 competitor groupings. Available under Commercial License.

Entity	TTM Revenue	Latest Q ×4	Rev Run-rate vs TTM	TTM Net Income	TTM Net Margin
Alterola Biotech Inc	$12,345M	$12,345M	+12.3% · Accelerating	$1,234M	12.3%
Competitors combined	$12,345M	$12,345M	+12.3% · Accelerating	$1,234M	12.3%

Competitor Financial Benchmarking

TTM revenue, run-rate and net margin benchmarking across Alterola Biotech Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Alterola Biotech Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Alterola Biotech Inc	-	-	-	Yes
Competitors combined (6)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

ALTA Stock Performance relative to its Competitors

ALTA Competitors (weighted) Percent change over the selected range

Alterola Biotech Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Competitors Combined
(0 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Alterola Biotech Inc	-	-
Competitors combined (5)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Alterola Biotech Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

5 Best-Performing Tracked Competitors, Trailing 12 Months

#	Competitor	TTM Share Price Return	vs U.S.A. 500
1	Mondel z International Inc	282.9%	Outperformed
2	Pepsico Inc	282.9%	Outperformed
3	Nightfood Holdings Inc	282.9%	Outperformed
4	The Simply Good Foods Company	282.9%	Outperformed
5	The Hain Celestial Group Inc	282.9%	Outperformed

Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Alterola Biotech Inc's best-performing tracked competitors requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API, trailing 12 months.

Alterola Biotech Inc's Comment on Competition and Industry Peers

Alterola operates in the cannabinoid-based and cannabinoid-like pharmaceutical medicine research and development sector, which is characterized by rapid technological advancements and intense competition. The company competes with multinational pharmaceutical firms, specialized biotechnology companies, and research institutions, including universities. Competitors may have developed or may develop drugs comparable to Alterola's pipeline candidates. Existing therapeutic treatments for conditions targeted by Alterola have been approved by regulatory bodies such as the FDA and EMA and are currently in use. The market for new treatments is highly competitive. Several U.S.-based companies are involved in cannabinoid-based drug development, including early-stage discovery and preclinical work with synthetic and plant-derived cannabinoids like CBD. The cannabinoid ingredient sectors in food and cosmetics are also competitive, particularly in regions where such products are legal. Established companies often have advantages in size, experience, cash flow, and institutional networks, with greater financial, technical, and human resources than Alterola.

Publicly Traded Peers of Alterola Biotech Inc

Revenue and income for trailing 12 months, in millions of $, except employees

Company	Market Cap	Revenues	Income	Employees
Alterola Biotech Inc	64,803.71	251.75	-2.88	-
Pepsico Inc	175,916.50	96,904.00	10,515.00	306,000
Mondel z International Inc	77,391.48	39,304.00	2,623.00	91,000
The Simply Good Foods Company	863.43	1,392.52	-201.72	328
The Hain Celestial Group Inc	44.45	1,351.78	-304.92	1,800
Nightfood Holdings Inc	7.23	6.16	-4.39	6
SUBTOTAL	319,026.80	139,210.21	12,623.59	399,134

1 more competitors available

Sources: Alterola Biotech Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on: September 26, 2026
Focus of this report: publicly traded companies. Ten additional tables on Alterola Biotech Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Alterola Biotech Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Medicines Co	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Alterola Biotech Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Alterola Biotech Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).

Company	Largest Segment	2nd Segment	3rd Segment
Pepsico Inc	PepsiCo Beverages North America 29.95 %	PepsiCo Foods North America 26.33 %	Europe, Middle East & Africa (Segment) 20.61 %
Mondel z International Inc	Europe 37.98 %	North America 28.46 %	Asia, Middle East and Africa 20.27 %
The Hain Celestial Group Inc	North America Segment 50.83 %	International Segment 49.46 %	-

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Alterola Biotech Inc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $

Company	Market Cap	Revenue / Employee	Income / Employee
Alterola Biotech Inc	64,804	-	-
Pepsico Inc	175,917	316,680	34,363
Mondel z International Inc	77,391	431,912	28,824
The Simply Good Foods Company	863	4,245,491	-615,003
The Hain Celestial Group Inc	44	750,991	-169,402
Nightfood Holdings Inc	7	1,026,879	-731,835
PEERS TOTAL	254,223	348,150	31,635

1 more Peers available

Alterola Biotech Inc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.

Company	Largest Market	2nd Market	3rd Market
The Simply Good Foods Company	North America 97.96 %	-	-
The Hain Celestial Group Inc	US 45.82 %	GB 35.59 %	Western Europe 13.87 %

Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Alterola Biotech Inc's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.

Metric	2015	2016	2017	2018	2019	2021	2022	2023
Revenue Growth	-	-	-	-	-	-	-	-
Operating Margin	-	-	-	-	-	-	-	-
Return on Invested Capital	6.59 %	-	12.25 %	102.62 %	87.12 %	5.05 %	-15.81 %	-41.62 %
P/E	-	-	-	-	-	-	-	-

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Alterola Biotech Inc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

Return on equity 193.7 points above the industry aggregate.

Weaknesses

Piotroski F-Score of 2 or below, the standard financial-distress signal.

Opportunities

No rule matched.

Threats

Tracked peer group's revenue run-rate is broadly decelerating (-4.2% annualized).

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Alterola Biotech Inc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months

Company	Quick Ratio	Working Capital	Debt / Equity	Asset Turnover
Alterola Biotech Inc	0.09	0.24	-	429.14
Pepsico Inc	0.28	0.90	2.46	0.89
Mondel z International Inc	-	0.59	0.81	0.55
The Simply Good Foods Company	0.99	4.18	0.20	0.62
The Hain Celestial Group Inc	0.09	0.86	3.38	0.99
Nightfood Holdings Inc	0.04	0.08	3.05	0.09

1 more Peers available

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Alterola Biotech Inc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter

Company	Period	Revenue Y/Y	Revenue Q/Q	Income Y/Y	Income Q/Q
Alterola Biotech Inc	Q3 2024	-	-	-	-
Pepsico Inc	Q2 2026	+6.4 %	+24.4 %	+134.9 %	+28.5 %
Mondel z International Inc	Q1 2026	+8.2 %	-4.0 %	+38.6 %	-15.7 %
The Simply Good Foods Company	Q2 2026	-6.2 %	+9.8 %	-	-
The Hain Celestial Group Inc	Q2 2026	-27.6 %	-22.0 %	-	-
Nightfood Holdings Inc	Q1 2026	-	+22.5 %	-	-
PEERS TOTAL		+6.4 %	+14.0 %	+137.3 %	+25.9 %

1 more Peers available

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Alterola Biotech Inc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter

Company	Period	Costs Y/Y	Costs Q/Q	Capex Y/Y	Capex Q/Q
Alterola Biotech Inc	Q3 2024	-	-	-	-
Pepsico Inc	Q2 2026	+7.4 %	+27.1 %	-9.4 %	+83.2 %
Mondel z International Inc	Q1 2026	+5.7 %	-3.5 %	+12.6 %	-21.6 %
The Simply Good Foods Company	Q2 2026	-0.5 %	+8.5 %	+12.1 %	-
The Hain Celestial Group Inc	Q2 2026	-29.7 %	-23.6 %	-25.9 %	-
Nightfood Holdings Inc	Q1 2026	-	-6.5 %	+29.3 %	-69.2 %

1 more Peers available

Alterola Biotech Inc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover

Company	ROA	ROI	ROE	Receivables Turnover	Inventory Turnover
Alterola Biotech Inc	-	-	-	-	-
Pepsico Inc	9.63%	13.23%	50.13%	7.78	7.17
Mondel z International Inc	3.68%	4.94%	10.07%	9.82	6.04
The Simply Good Foods Company	-	-	-	9.14	5.44
The Hain Celestial Group Inc	-	-	-	9.24	5.49
Nightfood Holdings Inc	-	-	-	54.78	6.45

1 more Peers available

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Alterola Biotech Inc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book

Company	P/E	Price / Sales	PEG	P/CF	Price / Book
Alterola Biotech Inc	30.35	257.41	3.38	-	-
Pepsico Inc	16.84	1.82	1.38	67.90	7.90
Mondel z International Inc	29.94	1.97	-	12,898.58	3.00
The Simply Good Foods Company	-	0.62	-	33.51	0.61
The Hain Celestial Group Inc	-	0.03	-	11.94	0.29
Nightfood Holdings Inc	-	1.17	-	5.28	0.09
PEERS AVERAGE	25.27	2.29		121.40	6.42

1 more Peers available

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.